University of Dundee

all News

July 2016

  • 01 Jul 2016

    Researchers in the laboratory of Dr. Satpal Virdee have published the first example of genetically encodable aminooxy functionality, which can be installed site-selectively into recombinant proteins using genetic code expansion technology. The findings were published in Chembiochem this week.

June 2016

  • 30 Jun 2016

    Satpal Virdee has been awarded a BBSRC Responsive Mode award of £650,000 allowing his lab to further develop technology they pioneered that enables the activity-based profiling of E3 ligases.

  • 30 Jun 2016

    Francesca Carrieri and Maithili Shroff to join Europe’s finest University students in creative and intellectual collaboration at Roche Continents 2016   Two Ph.D. students from Life Sciences at the University of Dundee have been invited to the highly prestigious Roche Continents - a full week of interdisciplinary challenges and inspiration at Roche Continents which takes place in Salzburg (during the Salzburg Festival) from 10th – 16th August 2016.  

  • 10 Jun 2016

    In ground-breaking new work published in Molecular Cell, Yogesh Kulathu and colleagues report the discovery of a completely new family of Deubiquitinating enzymes (DUBs). Ubiquitin signals impact a wide range of eukaryotic biology. It is therefore very important that these signals are tightly regulated. This layer of regulation is provided by dedicated proteases called deubiquitinating enzymes (DUBs), of which there are ~100 encoded in the human genome that can be classified into five families.

March 2016

  • 07 Mar 2016

    Pioneering chemical technology developed at the University of Dundee is giving scientists the clearest insight yet into crucial biochemical processes that are active in many diseases, including Parkinson’s disease.   Dr Satpal Virdee, leader of the research team, said their findings could `revolutionise’ research capability.   Already the Dundee team have used their newly developed tools to make new discoveries relating to the activity of the Parkin enzyme, which when mutated is a cause of Parkinson’s disease.

  • 07 Mar 2016

    The Royal Society of Edinburgh has announced today that four people from the University of Dundee have been elected as Fellows of the RSE, three of whom are from the Schools of Life Sciences.   The new Fellows from the University are:   ·         Wendy Alexander, Vice-Principal (International) ·         Paul Birch, Professor of Plant Pathology and Deputy Head of the Division of Plant Sciences

February 2016

  • 10 Feb 2016

    A Japanese delegation visite the Wellcome Trust Building at the University of Dundee to initiate a partnership seeking to develop new treatments for inflammatory diseases.   Scientists and executives from Ono, Japan’s oldest pharmaceutical company, met with Professor Sir Philip Cohen and leading researchers from the University’s School of Life Sciences to mark the start of the collaboration, which will see the Dundee team help Ono to launch a new drug discovery project.  

  • 04 Feb 2016

    Scientists at the University of Dundee have discovered that “molecular scissors” that repair damaged and abnormal DNA are critical for keeping cancers at bay.   The laboratory of Professor John Rouse at the University’s Medical Research Council Protein Phosphorylation and Ubiquitlation Unit (MRC-PPU) first discovered that a protein called FAN1 was important for cutting and repairing damaged DNA in our cells in 2010.  

  • 04 Feb 2016

    A University of Dundee researcher has been awarded a prestigious €2million grant to investigate how DNA becomes damaged, leading to ageing and disease.   Dr Helen Walden, of the University’s School of Life Sciences, has been awarded the European Research Council (ERC) Consolidator Grant. The highly competitive awards are given to the best and most creative researchers working in Europe.  

January 2016

  • 28 Jan 2016

    International Consortium Identifies and Validates Cellular Role of Priority Parkinson’s Disease Drug Target, LRRK2 Kinase   An international public-private consortium of researchers brought together by the University of Dundee and led by The Michael J. Fox Foundation for Parkinson’s Research has identified and validated for the first time the cellular role of a primary Parkinson’s disease drug target.